ReviewFrontiers in endocrinology2022
Novel biomarkers and therapeutic approaches for diabetic retinopathy and nephropathy: Recent progress and future perspectives.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of estimated glomerular filtration rate with proliferative diabetic retinopathy: a systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Functional Molecular Plasma Biomarkers of Inflammation and Repair in Kidney Disease Progression in Gum Arabica Modality of CKD.International journal of molecular sciences · 2026Article
- Development of a Glycated Albumin-Based Algorithm to Evaluate Diabetic Retinopathy in Adults with Type 2 Diabetes: A Cross-Sectional Study at a Hospital-Affiliated Physical Examination Center.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Precision Medicine in Diabetic Retinopathy: The Role of Genetic and Epigenetic Biomarkers.Journal of clinical medicine · 2025Review
- Inflammation and immune biomarkers: new frontiers in understanding and managing diabetes complications.Inflammopharmacology · 2025Review
- Increased tumor necrosis factor-receptor superfamily plasma levels are associated with early renal or retinal involvement in intermediate hyperglycemia.World journal of diabetes · 2025Article
- Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?Current atherosclerosis reports · 2025Review
- Retinal Biomarkers in Diabetic Retinopathy: From Early Detection to Personalized Treatment.Journal of clinical medicine · 2025Review
- Cuproptosis-related gene signatures define the immune microenvironment in diabetic nephropathy.PloS one · 2025Article
- Identification of hub genes in the crosstalk between type 2 diabetic nephropathy and obesity according to bioinformatics analysis.Adipocyte · 2024Article
- Retinal microcirculation changes in prediabetic patients with short-term increased blood glucose using optical coherence tomography angiography.World journal of radiology · 2024Article
- Exploring the role of Müller cells-derived exosomes in diabetic retinopathy.Microvascular research · 2024Article
- Interactive effect of phenylalanine with duration of diabetes on the risk of small vessel disease in Chinese patients with T2DM.Frontiers in endocrinology · 2024Article
- The automatic detection of diabetic kidney disease from retinal vascular parameters combined with clinical variables using artificial intelligence in type-2 diabetes patients.BMC medical informatics and decision making · 2023Article
- Improvement of microvascular complications in STZ-diabetic rats treated withBiochemistry and biophysics reports · 2023Article
- Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy.International journal of molecular sciences · 2023Review
- Pediatric Diabetic Nephropathy: Novel Insights from microRNAs.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global burden due to microvascular complications in patients with diabetes mellitus persists and even increases alarmingly, the intervention and management are now encountering many difficulties and challenges. This paper reviews the recent advancement and progress in novel biomarkers, artificial intelligence technology, therapeutic agents and approaches of diabetic retinopathy and nephropathy, providing more insights into the management of microvascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.